The application of such “edgetic” drugs has increased in recent years, especially for difficult but promising drug targets (like LFNG).31,55 This edgetic drug has the potential to promote and maintain the tumour suppressive inhibition of LFNG on the Jagged1-NOTCH1 signalling, while blocking the LFNG-NOTCH2 stimulatory interaction. This evidence concerns the gene JAG1 and neoplasm.